Skip to main content
MapleLMS Implementation
Conferences and Meetings 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

Short name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III
Course start date: 11/05/2025

Sections

General
0 activities

Activation of mTOR Signal Bolster Natural Killer Cell Immunity Against EBV-Infected B Lymphocytes
Expanding the Role of SH2B3: T Cell Large Granular Lymphocytosis (LGL) and Common Variable Immune Deficiency in the Setting of Biallelic SH2B3 Mutations
L-Asparaginase Treatment Induces Reversible Immunoregulatory and Immunosuppressive Effects in Non-Malignant B Cells in a Model of T-Cell Dependent B Cell Activation
Lymph Node Transcriptomics in Idiopathic Multicentric Castleman Disease (iMCD) Identifies Pathogenic Mechanisms and Biomarkers Including Increased Clusterin Expression
Multiplex Analysis of Peripheral Blood in Cancer Patients Predicts Humoral and Cellular Responses to Sars-Cov-2 Vaccines
Navigating Lineage Options: A Data-Driven Quest to Uncover T Cell Fate Decision Trajectories
Thymopoiesis-Associated Genetic Variant Correlates with Cancer Risk and Outcome
Trafficking, Not Lymphoproliferation, Promotes Lymphadenopathy in Idiopathic Multicentric Castleman Disease
Trials in Progress: A Phase 3 Study to Investigate Efficacy, Safety, and Tolerability of Mavorixafor in Participants with Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders